Kinarus Therapeutics Holding AG
SIX:KNRS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.792
30.464
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Kinarus Therapeutics Holding AG
Kinarus Therapeutics Holding AG
Investor Relations
Kinarus Therapeutics Holding AG, a biopharmaceutical company based in Switzerland, emerges at the crossroads of innovative science and unmet medical needs. The company is committed to pioneering novel therapies for chronic disorders, with a strong focus on ophthalmology and fibrotic diseases. At the heart of its operations lies an unwavering dedication to developing pharmaceuticals that can significantly improve patients' lives. Kinarus employs a distinctive approach by repurposing existing drugs, thereby accelerating the development process and reducing the inherent risks associated with new drug development. This strategy allows the firm to quickly advance its candidates through clinical trials, capitalizing on existing safety profiles while innovating in therapeutic efficacy.
The company's financial engine runs on a clinical-stage pipeline that harnesses the potential of drug candidates designed to tackle chronic and progressive conditions. Kinarus generates revenue primarily by advancing these candidates through different phases of clinical trials, aiming for favorable outcomes that will attract partnerships with larger pharmaceutical entities or lead to potential out-licensing agreements. As these collaborations materialize, Kinarus can secure milestone payments, royalties, and licensing fees, which feed back into its research and development endeavors. By striking a balance between scientific acumen and strategic partnerships, Kinarus Therapeutics continues to forge pathways in the biopharmaceutical sector, seeking not only to create financial value but also to deliver transformative solutions for enduring health challenges.
Kinarus Therapeutics Holding AG, a biopharmaceutical company based in Switzerland, emerges at the crossroads of innovative science and unmet medical needs. The company is committed to pioneering novel therapies for chronic disorders, with a strong focus on ophthalmology and fibrotic diseases. At the heart of its operations lies an unwavering dedication to developing pharmaceuticals that can significantly improve patients' lives. Kinarus employs a distinctive approach by repurposing existing drugs, thereby accelerating the development process and reducing the inherent risks associated with new drug development. This strategy allows the firm to quickly advance its candidates through clinical trials, capitalizing on existing safety profiles while innovating in therapeutic efficacy.
The company's financial engine runs on a clinical-stage pipeline that harnesses the potential of drug candidates designed to tackle chronic and progressive conditions. Kinarus generates revenue primarily by advancing these candidates through different phases of clinical trials, aiming for favorable outcomes that will attract partnerships with larger pharmaceutical entities or lead to potential out-licensing agreements. As these collaborations materialize, Kinarus can secure milestone payments, royalties, and licensing fees, which feed back into its research and development endeavors. By striking a balance between scientific acumen and strategic partnerships, Kinarus Therapeutics continues to forge pathways in the biopharmaceutical sector, seeking not only to create financial value but also to deliver transformative solutions for enduring health challenges.
Earnings Calls
You don't have any saved screeners yet
